Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

scientific article

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2004-02-0547
P698PubMed publication ID15217830
P5875ResearchGate publication ID8490130

P50authorKenneth C. AndersonQ28421846
Paul G. RichardsonQ87712102
Nikhil V MunshiQ89228014
Klaus PodarQ92660028
Robert SchlossmanQ114300414
Teru HideshimaQ114455520
Dharminder ChauhanQ117224711
Constantine S MitsiadesQ117224720
P2093author name stringGuilan Li
Finbarr E Cotter
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectmitochondrionQ39572
multiple myelomaQ467635
P304page(s)2458-2466
P577publication date2004-06-24
P1433published inBloodQ885070
P1476titleTargeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
P478volume104

Reverse relations

cites work (P2860)
Q46873208A new therapy with bortezomib, an oncologic medicinal product of the year 2004
Q24622083A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells
Q40102590A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
Q36807352Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.
Q33930178Apoptosis of multiple myeloma.
Q34786865Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway
Q37258248Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
Q40020547Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases
Q47804400Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
Q37223850Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model
Q35804471Integrated molecular profiling of SOD2 expression in multiple myeloma
Q37013815KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
Q41770950Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Q39184945Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells
Q39770370NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways
Q36636660New horizons in multiple myeloma therapy
Q34674973Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors
Q38238610Overcoming bortezomib resistance in multiple myeloma.
Q46643213PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor
Q35847659PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
Q42821645PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Q24814325Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Q34611676Proteasome inhibitors in the treatment of multiple myeloma
Q80337028Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria
Q37411350Proteasome regulators: activators and inhibitors.
Q64243018Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
Q35616060Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Q42037254The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib
Q46003331The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Q36887730The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines
Q91013801miR-22 suppresses DNA ligase III addiction in multiple myeloma

Search more.